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1. Introduction  
G protein-coupled receptors (GPCR) represent a large family of proteins that share a unique 
membrane topology made of seven transmembrane segments. These receptors are an 
evolutionary success as they constitute more than 1% of the genoma. In addition, the same 
structural archetype has been selected to recognize a large variety of ligands and to activate 
multiple intracellular cascades via the coupling to different G proteins. Accordingly, G 
protein-coupled receptors participate in a wide range of physiological functions. The 
corollary of this physiological importance is that many pathologies are linked to a 
dysfunction of these signalling pathways. Indeed, half of the pharmacological drugs used to 
treat human diseases corresponds to molecules which interact with this family of receptors. 
In this context, the discovery of new receptors not only has an evident physiological interest, 
but also represents a therapeutic potential by the development of new pharmacological 
agents. The discovery and history of apelin signalling provides the best example of the close 
relationship between basic research and its pharmacoclinical implications. 
2. Discovery of apelin signalling  
The discovery of apelin signalling began with the cloning of two orphan G protein-coupled 
receptors (Masri et al., 2005; Audigier, 2006). The amino acid sequence of these two receptors 
revealed the presence of seven hydrophobic domains which is in agreement with the unique 
membrane topology of GPCRs made of seven transmembrane segments (TM). These new 
GPCRs were cloned by a fishing strategy based on the use of degenerate primers directed 
against consensus sequences located in the transmembrane segments  (TM) (Figure 1). 
When searching for subtypes of the vasopressin receptors and using degenerate oligos 
based on the nucleotide sequence encoding the second and the seventh TM regions, one 
team cloned by serendipity from human genomic DNA a new orphan receptor that was 
named APJ (O'Dowd et al., 1993). Northern blot analysis with polyadenylated mRNA 
revealed an expression in different regions of the rat brain. 
In order to determine whether GPCR played a role in early embryogenesis, our laboratory 
looked for DNA fragments amplified from mRNAs extracted from Xenopus gastrulas 
between primers located in consensus sequences of TM 3 and TM 6 domains. One amplified 
fragment was used to clone a novel member of the GPCR family in amphibians that we 
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named X-msr for mesenchyme-associated serpentine receptor (Devic et al., 1996). 
Interestingly, alignment of the protein sequence and molecular phylogeny analysis clearly 
demonstrated that the amphibian receptor was homologous to the human APJ receptor and 
represented its amphibian orthologue. In addition, in situ hybridization detected very early 
transcripts after the midblastula transition, then in the ventro-lateral mesoderm and later in 
the lateral plate mesoderm. 
 
 
Fig. 1. Cloning of orphan G protein-coupled receptors. 
The arrows represent the location of the sequences from which the two primers were 
designed for PCR amplification. The pink arrows correspond to the primers used for cloning 
of the human receptor APJ. The green arrows correspond to the primers used for cloning of 
the amphibian receptor X-msr. 
 
 
Fig. 2. Isolation of the endogenous ligand. 
Apelin gene codes for a peptide of 77 amino acids (AA), which contains a signal sequence of 22 
AA (green). Cleavage of this signal peptide generates a propeptide of 55 AA (orange) having 
three basic doublets (blue). Proteolytic processing at the level of each basic doublet can produce 
three fragments of different length : apelin36 (red), apelin17 (grey) and apelin13 (black). 
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These receptors remained orphan until the identification of their endogenous ligand isolated 
several years later from stomach extracts (Tatemoto et al., 1998). The corresponding gene 
codes for a prepropeptide of 77 aminoacids (Figure 2) containing a signal peptide which 
addresses the proapelin to the secretory pathway. Then, the propeptide would be processed 
by proteolytic cleavage at the level of three basic doublets and thus generate apelin 
fragments of different size: apelin 36, apelin 17 and apelin 13.  
3. Apelin signalling and cell lineages  
3.1 Embryogenesis and cell lineages  
Although each animal model displays its own advantages and limits, their embryonic 
development displays strong similarities in the signalling pathways orchestrating and 
coordinating the migration and the differentiation of the different cell progenitors. 
In a schematic manner, embryogenesis begins with a totipotent cell, the fertilized egg, and 
ends up with the emergence of the different cell types of adult organism and their assembly 
into specialized organs. The first event is the formation of three embryonic layers, ectoblast, 
endoblast and mesoblast, which will generate separately and specifically their own cell 
subpopulations. Gastrulation is the downstream event by which the spatial organization of 
the cell layers is rearranged with ectoblast outside the embryo, endoblast inside, and the 
mesoblast in between. Then, each embryonic layer is subdivided into different areas of 
presumptive territories associated with the commitment of cell progenitors and the 
formation of cell lineages. Migration of these progenitors and their in situ differentiation will 
initiate the formation of organ primordia where several cell subtypes will assemble in a 
spatial and temporal manner in order to form the outline of the future organ. 
Mesoblast provides the best example of this regional subdivision linked to the emergence of 
pluripotent progenitors before the induction of specific cell lineages (Figure 3). Progressively 
after gastrulation, the mesoblast splits into several territories with different cell potency : axial, 
paraxial, intermediate and lateral plate mesoderms. 
 
 
Fig. 3. Mesodermal territories and cell lineages. 
After gastrulation, the mesoblast becomes subdivided into different regions that will 
generate separate progenitors at the origin of specific lineages. A particular emphasis is 
given for the derivatives of lateral plate mesoderm and the corresponding cell lineages. 
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The axial mesoderm strictly corresponds to the formation of a transient structure, the 
notochord. Segmentation of the paraxial mesoderm gives rise to the somites, which then 
develop into three distinct regions : the sclerotome, which becomes mesenchymal and is the 
precursor of vertebrae and ribs, the myotome which forms myoblasts (muscle precursors), and 
the dermatome precursor of subcutaneous tissue and skin. The intermediate mesoblast is 
linked to the formation of the urogenital system and serves as the origin of the kidney and 
gonads. The lateral plate mesoderm is composed of two layers : the somatopleure close to the 
ectoblast is involved in the formation of connective tissue and bones; the splanchnopleure 
lying on the endoblast takes part in the formation of the cardiovascular system via three cell 
lineages corresponding to hemopoïetic, myocardial and endothelial progenitors. In most 
lineages, commitment of mesodermal cells precedes migration of lineage progenitors to the 
sites of organ formation. At their final destination, these progenitors in situ differentiate into 
the corresponding cell subtype. 
3.2 Apelin signalling and endothelial lineage 
In Xenopus (Devic et al., 1996) as well as in mouse (Devic et al., 1999) and zebrafish (Scott et 
al., 2007), mRNA expression of apelin receptors is observed very early and is localized in the 
ventrolateral mesoderm at gastrulation stage. Accordingly, apelin receptor may represent a 
marker of the different lineages originating from this mesodermal territory, such as 
hemopoïetic, myocardial and endothelial lineages. In addition, apelin signalling may exert a 
function in the migration or commitment of these cell progenitors. 
Our preliminary experiments on the expression pattern of apelin receptor gene from the 
gastrulation stage to the larval stage clearly established that its later expression was 
intimately associated with the formation of blood vessels and heart (Devic et al., 1996). 
Indeed, the transcripts initially in the ventrolateral mesoderm are later detected in the lateral 
plate mesoderm at neurula stage and then in procardiac tube and forming blood vessels at 
larval stage. Interestingly, gene expression is strictly localized in the inner endothelium 
layer. Accordingly, we proposed that receptor gene expression traces an endothelial lineage 
originating from uncommitted mesodermal cells and ending in endothelial cells (Figure 4).  
 
 
Fig. 4. Expression of apelin receptor and endothelial lineage.  
The upper part shows the localization of apelin receptor transcripts determined by in situ 
hybridization during embryogenesis. The arrow from the larval stage shows that the vessel 
section was performed at this stage. The lower part is a schematic drawing of the cell events 
occurring along the endothelial lineage. 
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Indeed, a subpopulation of mesodermal cells are first specified in endothelial progenitors, 
the angioblasts, which migrate to the sites of vessel formation. Organization of these 
endothelial progenitors in tubules and their in situ differentiation into endothelial cells 
correspond to the formation of the primary vascular network. 
The involvement of apelin signalling in this endothelial lineage is further confirmed by the 
blockade of gene expression using morpholino antisense probes during Xenopus 
embryogenesis. This experimental inhibition of the ligand or the receptor mRNA leads to a 
disruption of embryonic vessels (Cox et al., 2006). An additional proof of the vascular role of 
apelin signalling is revealed by the phenotype of apelin-deficient mice, which corresponds 
to a retardation of the development of some retinal vessels (Kasai et al., 2008). 
3.3 Apelin signalling and other lineages  
As mentioned before, mesodermal cells from the ventrolateral region not only contributes to 
endothelial lineage but also to hemopoïetic and myocardial lineages. This common origin 
together with the pluripotency of these cells have fully challenged the idea of lineage 
specificity. Indeed, the concept of hemangioblast, a bipotential progenitor of hemopoïetic 
and endothelial lineages has been validated by various approaches (Jaffredo et al.,  2000; 
Mandal et al., 2004). 
Interestingly, such a link between the three lineages has been revealed by a study performed 
on apelin signalling in Xenopus. Gene inactivation of apelin or its receptor results in a 
severe phenotype, which corresponds to an attenuated expression of endothelial, 
hemopoïetic and myocardial markers (Inui et al., 2006). Such an unexpected relationship 
between endothelial and myocardial lineages is further illustrated by the concomitant 
expression of apelin receptors by myocardial and endothelial progenitors. But apelin 
receptors are not simple markers and they also play an active role in the migration of 
myocardial progenitors : functional inactivation of apelin receptors impairs the migration of 
these progenitors to the sites of heart formation (Scott et al., 2007; Zeng et al., 2007).  
A very recent study has identified a common precursor of endothelial and mesenchymal 
cells, which was named mesenchymoangioblast. Previously, a late mesodermal precursor 
expressing Flk1 receptor was characterized by its potential to differentiate into endothelial 
cells, blood cells and mesenchymal cells (Minasi et al., 2002). However, the early precursors 
of this Flk1+ mesoderm subpopulation remained to be isolated. Surprisingly, it is expression 
of apelin receptor that identifies this mesodermal population of early bipotential progenitors 
giving rise to mesenchymal stem cells and angioblasts (Vodyanik et al., 2010). 
4. Apelin signalling and the formation of blood vessels  
4.1 The embryonic formation of blood vessels  
The vasculature of the body is a highly organized system and its anatomy is referred to as 
the vascular tree. Blood vessels are ranging from the simplest structures with a single 
endothelial layer, the capillaries, to complex structures, the large vessels made of different 
cell layers (endothelial, mural and elastic), such as aorta (Figure 5). 
The first step of blood vessel formation corresponds to the formation of the primary 
vascular network and is named vasculogenesis (Figure 6). This process results from the 
migration of endothelial progenitors, the angioblasts, to the sites of vessel formation and 
their in situ differentiation into endothelial cells. Concomitantly, these angioblasts or 
endothelial cells assemble together and participate in the formation of tubes or cord-like 
structures, which will later acquire a lumen.  
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Fig. 5. Vascular tree and vessels. 
The left part shows the different arterio-venous elements of the vascular system and 
includes lymphatic vessels. On the right part are given the vascular structure and layer 
organization related to the different sizes of vessel . 
The second step involves extension and remodelling of the primary network and is named 
angiogenesis (Figure 6). This process is driven by the increase of embryo size, which 
requires an adjustment of the oxygen demand and nutrient supply by the vessels to the 
increased metabolism of the growing tissues and organs. The stability of this mature 
network is provided by the recruitment of mural cells (pericytes or smooth muscle cells), 
which will form the second layer of the vessels and induce the quiescence of endothelial 
cells. Indeed, the proliferation index of the endothelial cells is the lowest among the various 
cell types of the body. 
 
 
Fig. 6. The two steps of vessel formation. 
The upper part describes the first step called vasculogenesis that is involved in the 
formation of the primary vascular network. The lower part concerns the second step called 
angiogenesis, which corresponds to remodelling of the primary network and the formation 
of the mature vascular tree. 
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All these cell events are orchestrated and finely tuned by various signalling pathways. The 
VEGF pathway plays a crucial role during vasculogenesis as well as angiogenesis (Ferrara et 
al., 2003). Through activation of the VEGFR2, Vascular Endothelial Growth Factor (VEGF) 
induces the differentiation, proliferation and migration of endothelial cells during vessel 
formation. In the maturation process, the recruitment of mural cells is mediated by the 
PDGF pathway (Figure 7).  
 
 
Fig. 7. Maturation and stabilization of vascular structures. 
The upper part corresponds to the maturation phase. Endothelial cells (EC) secrete PDGF-
BB, which is a chemotactic factor for mesenchymal cells. This migration is followed by an in 
situ differentiation into mural cell. The lower part describes the stabilization phase. The first 
event is release of angiopoïetin 1 (Ang1) by the mural cell, which then activates its Tie2 
receptor expressed at the surface of the endothelial cell. Ang1 pathway strongly reinforces 
the association between the two cell types. The second event corresponds to the TGF-
induced quiescence of the endothelial cell whereby TGF released by mural cell activates its 
receptor expressed by EC. 
Endothelial cells release Platelet-Derived Growth Factor (PDGF-BB), thereby attracting the 
mural cells which express its cognate receptors (Lindahl et al., 1997). The stabilization of the 
vascular structure is accomplished by a strong interaction between the endothelial cell and 
the mural cell, which relies on angiopoïetin pathway (Figure 7). Cell adhesion between these 
two cell types results from the angiopoïetin 1 release by mural cell, which then stimulates its 
Tie2 receptor expressed at the surface of the endothelial cell (Dumont et al., 1994; Sato et al., 
1995; Suri et al., 1996). This constitutive dialogue via the ligand and its receptor is the 
molecular basis of the stabilization of vessel structure. The concomitant quiescence of the 
endothelial cell is induced by another factor, TGF which is secreted by the mural cell and 
activates its receptor expressed at the surface of the endothelial cell (Figure 7). 
In parallel, the different caliber of blood vessels must be precisely controlled during the 
maturation process. Again, the Ang1/Tie2 pathway is a potent regulator of the enlargement 
of vessel caliber (Suri et al., 1996; Cho et al., 2005; Thurston et al., 2005). 
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In the adult organism, physiological and pathological situations are associated with 
regression or extension of the vascular network (see Figure 12). These changes are initiated 
by disruption of the mural/endothelial interaction, which involves an another angiopoïetin, 
Ang2, acting as an endogenous antagonist of Tie2 receptor (Maisonpierre et al., 1997). 
Accordingly, the alternate ligand use in the same pathway either reinforce or disrupt a cell 
interaction, which is central in the stability of blood vessel and remodelling of the vascular 
network.  
4.2 Apelin signalling and the formation of blood vessels  
So far, there is no clear evidence that apelin signalling plays a role during vasculogenesis. 
As mentioned before, expression of apelin receptors traces the endothelial lineage from 
unspecified mesodermal cells to differentiated endothelial cells (Devic et al., 1996, 1999). In 
Xenopus, blockade of gene expression gave controversial results, from full suppression of 
three cell lineages (Inui 2006) to a restricted angiogenesis defect (Cox et al., 2006). In 
addition, the phenotypes of gene invalidation in mouse are very mild, ranging from 
retardation of the formation of retinal network (Kasai et al., 2008) to a mild consequence on 
blood pressure (Ishida et al., 2004). On the other hand, it has been proposed that the severity 
of the vascular defects may depend on the genetic background of the invalidated mice. 
Accordingly, although apelin receptor is a marker of vasculogenesis, it may be a dispensable 
actor in this early process of vessel formation. 
As far as angiogenesis is concerned, the role of apelin signalling is well documented, and a 
large body of evidence reveals that apelin displays all the properties required for an 
angiogenic factor. As mentioned before, the endothelial cell is the first cell type which 
appears during vasculogenesis and represents the organizing center of the vascular 
structure during angiogenesis. In the adult, proliferation or apoptosis of endothelial cells is 
also the cell basis of tissue plasticity and vessel remodelling : their proliferation induces 
extension of the vasculature and their apoptosis promotes regression of the vasculature (see 
figure 12). Accordingly, it can be assumed that any angiogenic factor must have its cognate 
receptors expressed by the endothelial cell and that stimulation of these receptors by their 
ligand promotes a proliferative response. In addition to the characterization of receptor 
expression by the endothelial cells (Devic et al., 1996, 1999), our laboratory was the first to 
show that apelin induces the phosphorylation of ERK proteins (Masri et al., 2002, 2006) and 
behaves as a mitogenic peptide for primary cultured umbilical endothelial cells (Masri et al., 
2004) (Figure 8). At the same time, another group published that apelin induces the 
proliferation of an immortalized endothelial cell line (Kasai et al., 2004).  
These results at the cell level have been extended to the whole vessel : a large number of in 
vitro assays such as matrigel plug assay (Kasai et al., 2004) and in vivo studies such as ectopic 
apelin expression (Cox et al., 2006) has strongly confirmed the angiogenic activity of apelin 
peptide (Figure 8). Altogether, these data clearly demonstrate that apelin signalling fulfil at 
the protein level all the criteria required for an angiogenic pathway and represents a 
significant actor of physiological angiogenesis during embryonic development. 
A more recent study has revealed that apelin also regulates the caliber size of blood vessels by 
inducing their enlargement (Kidoya et al., 2008). Indeed, we also observed a similar 
phenomenon during tumour neoangiogenesis, as overexpression of apelin not only promotes 
an extension of the vascular network but also increases the number of large vessels (Sorli et al., 
2007)(see figure 14). Since the Ang1/Tie2 pathway regulates enlargement of vessel caliber, a 
link between this pathway and apelin signalling was expected. Indeed, Ang1 was found to 
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upregulate apelin gene expression in endothelial cells (see figure 17) and apelin expression 
was increased in Ang1 overexpressing transgenic mice (Kidoya et al., 2008). 
 
 
Fig. 8. Mitogenic and angiogenic activities of apelin. 
The upper left panel shows the time dependent phosphorylation of ERKs induced by apelin 
(determined by immunoblotting). The lower left panel corresponds to thymidine 
incorporation, an index of cell proliferation, measured in umbilical endothelial cells in the 
absence or presence of apelin. The upper right panel shows the angiogenic effect of apelin in 
the chorioallantoïc membrane of chicken. The lower right panel gives the quantitative 
analysis based on the calculation of vessel branching. 
4.3 Hypoxia and angiogenesis 
In the adult, the vascular system is quiescent and the proliferative index of endothelium is 
very low. Several physiological or pathological stimuli may promote the proliferation of 
endothelial cells and reactivate the angiogenic process. But this reactivation should logically 
recapitulate the same events and use the same mechanisms operating during the embryonic 
formation of blood vessels. 
The formation of retinal vessels has been the cornerstone for two fruitful hypothesis. A 
first observation was that extension of the retinal vasculature strictly follows the 
centrifugal extension of the nervous retina (see Figure 10). A proposed explanation was 
that a vasotropic substance released by neural cells exerted a chemotactic and 
proliferative effect on the vessel. As it was already discussed, the concept of a vasotropic 
substance is simply the ancient denomination for an angiogenic factor. More interestingly, 
the second hypothesis was on the nature of the driving force initiating the angiogenic 
process. Indeed, extension of nervous tissue increased the oxygen demand and thus the 
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growth-induced hypoxia might be the stimulus for reactivating angiogenesis. However, 
the molecular link between hypoxia and the angiogenic factor remained to be 
characterized. 
In 1992, Shweiki et al. described that hypoxia was able to upregulate the expression of the 
VEGF gene, the major angiogenic factor. Such an upregulation of VEGF gene was also 
reported in the hypoxic regions inside tumours (Plate et al., 1993). Consequently, it 
established a direct relationship between hypoxia and angiogenesis and provided an 
explanation for the adjustment of the vascular network to the increased oxygen 
consumption resulting from tissue growth (Figure 9).  
 
 
 
Fig. 9. Hypoxia and vascular homeostasis. 
The figure illustrates the relationship between expression levels of VEGF gene and 
adjustment of vessel number during the angiogenic phase. Tissue growth generates tissue 
hypoxia which induces expression of VEGF gene. VEGF stimulates the formation of new 
vessels which become excendentary and thus the subsequent hyperoxia downregulates 
VEGF expression. Different cycles of VEGF upregulation and downregulation occur until 
formation of the definitive network, which is then stabilized by coverage of the endothelial 
layer by mural cells. 
More recently, the various intermediates involved in the transduction of the hypoxic 
stimulus and overexpression of the VEGF gene have been characterized. The central protein 
in this regulation is a heterodimeric transcription factor named Hypoxia Inducible Factor 1 
(HIF-1). The protein complex consists of a hypoxically inducible subunit HIF-1 and a 
constitutively expressed subunit HIF-1 (Wang et al., 1995). Although the transcription and 
the synthesis of HIF-1 are constitutive, it has in normoxia a short half-life due to its 
targeting to and degradation by the proteasome (Wang et al., 1995). Several post-
translational modifications are necessary for targeting the  subunit to the proteasome, but 
the most relevant is hydroxylation by prolyl hydroxylases (Masson et al., 2001). Indeed, this 
oxygen-dependent modification initiates a complex series of molecular interactions which 
ultimately end up in subunit ubiquitination and proteasome degradation. As hydroxylation 
requires sufficient oxygen levels, this reaction is inhibited in hypoxic conditions. 
Consequently, HIF-1 becomes stabilized and translocates to the nucleus where its 
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dimerization with HIF-1 generates a transcriptionally active HIF complex (Huang et al., 
1996; Kallio et al., 1997).  
As many transcription factors, HIF complex selectively recognizes and binds to discrete 
DNA sequences located in the promoter or enhancer elements of target genes. These 
consensus sequences have been identified and named Hypoxia Responsive Elements 
(HRE)(Semenza et al., 1994). As it could be anticipated, the presence of HRE was detected in 
the genes encoding angiogenic factors, notably that of the VEGF gene (Levy et al., 1995). 
All these results provide a very simple and adaptative mechanism, which ensures a direct 
causal relationship between hypoxia and angiogenesis in order to achieve a fine homeostasis 
between oxygen demand of growing tissues and oxygen supply by blood vessels. 
4.4 Hypoxia and apelin expression   
The corollary of the previous findings is that the gene encoding any angiogenic factor has to 
contain HRE sequences and to be induced by hypoxia. 
In view of the angiogenic role of apelin, several studies have been performed in order to 
characterize an upregulation of apelin gene under hypoxic conditions. The results clearly 
showed that hypoxia increases apelin mRNA levels via HIF protein in different cell types, 
but with varying intensity ranging from a 2-fold to 30-fold increase (Cox et al., 2006; Sorli et 
al., 2007; Ronkainen et al., 2007;  Glassford et al., 2007; Sheikh et al., 2008; Eyries et al., 2008). 
In addition, gene upregulation at the mRNA level is accompanied by a subsequent increase 
of peptide synthesis and secretion (Ronkainen et al., 2007;  Sheikh et al., 2007). 
A bioinformatic analysis has corroborated these experimental data by identifying the presence 
of putative HRE sequences in apelin gene (Cox et al., 2006). In addition, a functional HRE was 
mapped within the first intron by reporter constructs and the binding of HIF-1 to this HRE 
was demonstrated by chromatin immunoprecipitation (Eyries et al., 2008). 
4.5 Retinal vessels and endothelial subpopulations  
The retinal vasculature of mouse represents an interesting model system used for the study 
of blood vessel formation. In contrast to the embryo, the vessels are readily accessible as 
their formation occurs postnatally, and whole mount retinas allow to characterize the 
spatio-temporal expression of genes by in situ hybridization or proteins by 
immunohistochemistry (Figure 10). 
Interestingly, a study on the formation of retinal vessels has revealed the presence of two 
distinct endothelial populations, which differ in their morphology and their functional 
specialization (Gerhardt et al., 2003). Endothelial cells at the front of migrating vessels, 
called tip cells, possess cell protrusions (filipodia) and their function is specialized in the 
decoding of chemotactic signals and polarized extension of the network (Figure 11). 
Underneath, the other endothelial cells, called stalk cells, do not have a particular 
morphology and their function is to proliferate in order to provide the new endothelial cells 
that are required for extension of retinal vasculature (Figure 11). 
4.6 Apelin signalling and endothelial subpopulations  
In this retinal model, the spatio-temporal expression of apelin and its receptor displays a 
very interesting pattern (Saint-Geniez et al., 2002). Ligand and receptor mRNA expression is 
selectively upregulated during the formation of retinal vessels and downregulated after 
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maturation and stabilization of the retinal network (Figure 10). Again, these observations 
confirm that apelin signalling is activated during the angiogenic phase and desactivated 
when the vessels become quiescent. 
 
 
 
 
Fig. 10. Retinal model and apelin signalling. 
Upper panel illustrates the vascular networks of retina. Nervous retina is irrigated by two 
vascular networks, the retinal vessels and the choroïdal vessels. In mouse, the postnatal 
formation of the retinal network proceeds in a centrifugal manner from optic disk at birth to 
the periphery at postnatal day 10 (P10). Lower panel shows the spatio-temporal expression 
of apelin receptor gene during formation of retinal vessels. Note the downregulation 
observed after the onset and stabilization of the retinal network at P15. 
In addition, expression pattern of apelin and its receptor was spatially different, even inside 
the endothelium (Saint-Geniez et al., 2002) (Figure 11). Apelin expressing endothelial cells 
were localized at the leading edge of the retinal vascular network, whereas receptor 
expression was mainly observed in the underneath endothelial cells. Using a specific 
fluorescent lectin for labelling endothelial cells, we detected high apelin expression levels in 
tip cells easily recognized by their filipodia. On the other hand, we were unable to detect 
apelin receptor transcripts in this first row of endothelial cells, whereas receptor expression 
was observed in the other endothelial cells of the vascular network, previously referred to as 
stalk cells (Sorli et al., 2006). 
According to this expression pattern and the proposed role of VEGF as the chemotactic 
signal for the polarized extension of the vascular network, we proposed a model in which 
apelin would be the downstream molecule transmitting the proliferative signal from tip 
cells to downstream stalk cells. 
www.intechopen.com
 Apelin Signalling: Lineage Marker and Functional Actor of Blood Vessel Formation 85 
 
 
Fig. 11. Apelin signalling and endothelial subpopulations. 
The upper left panel is a schematic representation of the formation of retinal vessels (green) 
driven by extension of the nervous retina (red). The upper right panel is a magnification of 
the migrating front of endothelial cells, with the tip cells at the leading edge and the 
underneath stalk cells. The lower part shows the gene expression of apelin in the front at the 
tip cell level (left) and apelin receptor underneath in the stalk cells (right). 
5. Apelin signalling and vascular pathologies  
5.1 Vascular pathologies 
Besides its involvement in vessel formation, the endothelial cell is the integration center of 
vascular plasticity. The integration of various environmental stimuli defines its cellular 
response, proliferation or apoptosis, which will lead to the corresponding modification of 
the vascular network, extension or regression (Figure 12). 
According to the previously described role of Ang2, its expression is increased by these 
activating environmental stimuli in order to disrupt vessel stability and initiate the vascular 
plasticity (Maisonpierre et al., 1997). The qualitative change of vascular network depends on 
the growth factor (GF) “context”, which will orientate the vascular system to either 
extension in high GF levels or regression in low GF levels (Figure 12). 
These two different modifications of the vascular network divide the vascular pathologies 
into ischemic diseases associated with a vessel defect and neovascularisation linked 
pathologies associated with a vessel excess. The ischemic pathologies primarily concern two 
organs, heart and leg muscle. The treatment of these pathologies requires therapeutic 
angiogenesis which is achieved by the use of receptor agonists of angiogenic pathways. The 
opposite pathologies that are characterized by neovascularisation represent more frequent 
and severe diseases, such as tumour neovascularisation, diabetic retinopathies and age-
related macular degeneration (AMD). For them, the therapeutic strategy is the 
administration of antiangiogenic molecules, such as antagonists of receptors mediating 
angiogenic signals. 
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Fig. 12. Vessel plasticity and vascular pathologies. 
The figure illustrates how the growth factor “context” drives the fate of vessel plasticity. 
Destabilization is first initiated by expression of angiopoïetin2 (Ang2) which disrupts the 
interaction between EC and mural cells. Low levels of VEGF induce endothelial apoptosis and 
lead to regression of vascular network, a situation that occurs in the ischemic diseases. In high 
levels of VEGF, endothelial cells proliferate, new vessels are formed, and this abnormal 
extension of the vascular network recapitulates what happens in the neovascular pathologies. 
5.2 Apelin signalling and vascular pathologies  
5.2.1 Apelin signalling and ischemic pathologies  
Apelin is a potent activator of cardiac contractility (Szokodi et al., 2002), suggesting the 
possible involvement of apelin signalling in ischemic heart failure. Such a role is 
corroborated by the upregulation of apelin receptor gene in left ventricule and an increase of 
apelin plasma levels in left ventricular dysfunction. In addition, apelin released from the 
endothelium of the coronary arteries would locally act in a paracrine manner on myocardial 
tissue (Chen et al., 2003).  
Similar data have been obtained in ischemic heart failure : total myocardial amounts of 
apelin and apelin receptor proteins increase in compensation of heart failure (Atluri et al., 
2007). The stimuli (including tissue hypoxia) associated with heart failure upregulate 
transcription of ligand and receptor genes and increase their protein expression (Sheikh et 
al., 2008). As apelin signalling is activated for protecting the heart against ischemia injury, 
the effect of infusion of the endogenous agonist apelin13 was tested after ischemia. 
Interestingly, apelin not only limited infarct size but also improved cardiac postischemic 
mechanical recovery (Rastaldo et al., 2011)(Figure 13). 
In limb ischemia, therapeutic angiogenesis using local delivery of genes encoding 
angiogenic factors or systemic injection of their recombinant proteins has proved its 
efficiency in promoting the revascularization of ischemic territories. In a mouse model of 
limb ischemia, coadministration of apelin and VEGF improves the revascularisation of the 
ischemic limb and induces an increase of vessel size (Kidoya et al., 2010) (Figure 13). 
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5.2.2 Apelin signalling and tumour neovascularisation 
As formulated by Folkman in 1971, the survival and growth of solid tumours depend on the 
formation of new vessels, which are necessary to compensate the increased oxygen demand 
of this highly proliferative tissue. The corollary of this hypothesis is that tumoral cells 
secrete angiogenic factors in order to attract host vessels and create tumoral vessels. As 
described for physiological angiogenesis, one activating stimulus is hypoxia occuring in the 
center of tumour because of its maximal distance from vessel supply.  
 
 
 
Fig. 13. Effects of apelin in ischemic diseases. 
The left part shows that the size of infarct trigged on isolated hearts is reduced by 
perfusion of apelin. The right part describes the angiogenic effects of apelin in limb 
ischemia model. Doppler images demonstrates an increase of blood flow following apelin 
gene transfer, which is confirmed by quantification of laser Doppler-monitored blood 
flow measurements. 
In order to address whether apelin secreted by tumoral cells may possess a neoangiogenic 
activity, we developed two mouse models of tumour neovascularisation. Stable clones of 
B16 melanoma cells and TS/A mammary adenocarcinoma cells overexpressing apelin were 
created and their tumour growth was compared to that of clones transfected with the empty 
plasmid (named mock) (Sorli et al., 2006, 2007). Apelin overexpression clearly accelerates 
tumour growth in vivo and this effect results from a paracrine action on endothelial cells of 
host vessels (Sorli et al., 2007) (Figure 14). In addition, the number of small vessels decreases 
whereas that of large vessels increases (Figure 14). 
The pathological relevance of apelin signalling in tumour neovascularisation was 
suggested by gene upregulation of apelin and its receptor in malignant gliomas, which 
represent highly vascularised tumours (Kälin et al., 2007). Moreover, a cancer profiling 
array revealed a clear upregulation of apelin gene in one third of human adenocarcinomas 
(Sorli et al., 2007). As far as pulmonary tumours are concerned, a recent study has 
confirmed that apelin mRNA levels were significantly increased in human non-small cell 
lung cancer (Berta et al., 2010). Interestingly, the extent and the frequency of apelin gene 
upregulation in a cancer profiling array was dependent on the tissue origin of the tumoral 
cells, the highest frequency being observed in colon (50%) and pancreas (71%)(Figure 15).  
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Fig. 14. Apelin overexpression and tumour neovascularisation. 
Left part illustrates the acceleration of in vivo tumour growth in tumours derived from tumoral 
cells overexpressing apelin when compared to the animals injected with empty plasmid 
transfected tumoral cells (Mock). Overexpressed apelin acts on the vascular component of the 
tumour by increasing the total number of vessels as revealed by immunostaining with the 
endothelial marker CD31 (upper right panel). As shown in lower right panel, it also modifies 
caliber of the neovessels by increasing the number of large vessels (300-1000 2). 
 
 
Fig. 15. Upregulation of apelin gene and tumour growth. 
Two distinct modes of gene upregulation can occur during tumour neovascularisation.  
The hypoxia-induced upregulation is spatially restricted (yellow cells) and likely 
independent of the tissue origin of tumoral cells. The lower left panel shows the hypoxia-
induced upregulation of apelin gene in TS/A mammary adenocarcinoma cells. On the other 
hand, gene upregulation may result from the genetic changes leading to the cell transformation 
and thus becomes constitutive (right panel). In this situation, upregulation is ubiquitous  
(yellow cells) and tissue dependent. As shown in the lower right panel, upregulation of apelin 
gene varies in frequency and amplitude from one tumoral tissue to the other.  
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As the center of all tumours is hypoxic, the tissue dependent variations of gene upregulation 
may rather be a direct consequence of the genetic alteration(s) occurring in the genomic DNA 
(Figure 15). Indeed, activation of oncogenes or inactivation of tumour suppressors also leads to 
the upregulation of genes coding for angiogenic factors (Rak et al., 1995; Brugarolas  Kaelin, 
2004). However, such a link between genetic alterations and upregulation of apelin gene 
remains to be established. Altogether, the variable upregulation of apelin gene observed in 
human tumours may result from both genetic factors and environmental stimuli, including 
hypoxia. 
5.2.3 Apelin signalling and retinal neovascularisation  
Nervous retina is irrigated by two vascular networks, the retinal and the choroïdal 
vasculatures. The postnatal formation of retinal vessels begins at birth from the optic disk 
and the growing network extends in a centrifugal manner to the periphery of the retina. 
During formation of retinal vessels, gene expression of apelin receptor on pup retinas traces 
the centrifugal extension of this retinal network (see figure 10). 
 
 
Fig. 16. Apelin signalling and retinal neovascularisation. 
The upper part describes the different steps in the mouse model of retinal neovascularisation. 
Hyperoxia is made between postnatal day 7 (P7) and postnatal day 12 (P12) (green) and leads 
to vessel regression as shown by a fluorescent marker of endothelial cells. Return to normoxia 
corresponds to a relative hypoxia, which triggers the formation of neovessels in a centripetal 
manner (see the network labelled with the fluorescent probe at P15). From P17 to P23, 
extensive remodelling allows recovery from hyperoxia and the retinal network becomes 
normal (see the network labelled with the fluorescent probe at P23). In the upper part are 
reported the concomitant variations of VEGF levels occurring at the different steps of 
neovascularisation. The lower part shows the variations of apelin receptor expression from 
return to normoxia until normalization of the vascular network 
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The main pathological defect affecting this retinal network is observed in diabetic patients 
where there is an abnormal formation of new retinal vessels leading to cecity. A mouse 
model reproducing the main features of this retinal pathology has enabled the dissection of 
the molecular and cellular events during the onset and the development of this pathology 
(Smith et al., 1994) (Figure 16). Hyperoxia treatment of seven-day-old mice for five days 
induces endothelial apoptosis and decreases the number of retinal vessels. Return to 
normoxia corresponds to a form of hypoxia in the mid-retina, which upregulates the 
expression of VEGF gene and promotes the formation of new vessels. According to the 
localization of the ischemia in the mid-retina, the normal centrifugal extension of the 
forming vasculature is reversed to a pathological centripetal extension. 
Interestingly, expression of apelin receptor gene is highly upregulated in these new vessels 
and strictly follows the centripetal extension of the retinal network (Sorli et al., 2006). In 
addition, quantitative analysis of apelin mRNA levels revealed a very strong increase (31-
fold) during the hypoxic phase; furthermore, in apelin-deficient mice, there was no increase 
in capillary density and abnormal vessels during the hypoxic phase (Kasai et al., 2010). 
Accordingly, systemic or local injection of antagonists of apelin receptor is a promising 
therapy for blocking the formation of new retinal vessels in diabetic retinopathies. 
5.2.4 Apelin signalling and choroïdal neovascularisation 
A frequent pathology of the elderly is the formation of excedentary vessels in the choroïdal 
network, which is appropriately named age-related macular degeneration (AMD). At the 
present time, there is no immunohistochemical study on the expression of apelin or its 
receptor in endothelial cells lining the choroïdal vessels. The only related observation is that 
apelin induces the proliferation of the immortalized choroïdal endothelial cell line RF/6A, 
suggesting expression of apelin receptors at the surface of these cells (Kasai et al., 2004). 
However, it can be assumed that the pathological angiogenesis occuring in AMD should 
involve the same angiogenic pathways that are activated in the formation of new vessels in 
the retinal network, including apelin signalling pathway. 
6. Cross-talk between angiogenic pathways  
Apelin clearly represents one of the various actors that participate in the formation of blood 
vessels. However, the respective role of each angiogenic pathway, including apelin 
signalling, as well as their synergic activity, remains to be elucidated. 
A specific property of apelin peptide seems to be its ability to regulate the caliber of blood 
vessels by promoting the formation of enlarged vessels during physiological (Kidoya et al., 
2008) and pathological (Sorli et al., 2007) angiogenesis. This vessel enlargement is one 
mechanism by which hemodynamic changes can respond to an increase of oxygen demand. 
But this effect may be indirect and due to the consequences of its cross-talk with other 
angiogenic pathways such as that of VEGF and Ang1 (Figure 17). The initiator of the 
angiogenic process would be VEGF, which induces the sprouting of endothelial cells from 
mature vessels and the concomitant expression of apelin receptor. Then, Ang1 via activation 
of its Tie2 receptor triggers the expression of apelin, which becomes secreted outside the 
endothelial cell. The synergic action of VEGF and apelin would lead to the proliferation of 
EC and the formation of cell to cell contacts. In this scenario, the precise role of apelin 
signalling would concern the mobilization of ECs in this assembly process and the 
construction of enlarged vessels. 
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Fig. 17. Cross-talk between angiogenic pathways. 
An hypoxic cell or a tumoral cell expresses VEGF gene in an induced or constitutive 
manner, respectively. Then VEGF activates its receptor expressed by the endothelial cell 
(EC), leading to increased expression of apelin receptor. In parallel, Ang1 expressed by 
mural cells stimulates its receptor Tie2 at the surface of EC, leading to an increased release 
of apelin. Apelin released in the medium can activate the same EC in an autocrine manner 
or another EC in a paracrine manner. All these interactions between angiogenic pathways 
result in vascular changes, such as vessel sprouting, EC-EC assembly and vessel 
enlargement. 
As mentioned before, induction of genes encoding angiogenic factors by hypoxia clearly 
represents a crucial mechanism leading to an increased oxygen supply via extension of 
vascular network. However, the level of hypoxia-induced upregulation in the same cell or in 
various cell subtypes may vary from one angiogenic factor to the other, and thus their 
respective contribution may be modulated by the nature of the environmental stimuli. A 
same statement can be applied to tumoral cells where the genetic alterations may 
constitutively upregulate some angiogenic genes. In addition, as this transformation-
induced modifications are extended to all tumoral cells and not restricted to the center of the 
tumour, the role of a specific angiogenic factor may be selectively enhanced, thereby 
representing a more relevant therapeutic target. 
7. Therapeutic potential of apelin signalling in vascular diseases  
As mentioned before, upregulation of the expression of apelin and its receptor is intimately 
associated with the angiogenic phase of vessel formation or remodelling, and their 
downregulation follows maturation and stabilization of the vascular structures.  
These two observations have theoretical and practical consequences for vascular 
pharmacology. First, it reveals that apelin signalling is not a constitutive pathway at the 
vascular level and rather behaves as an adaptative pathway only activated during vascular 
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plasticity. Second, the expression upregulation and activation of apelin signalling during 
angiogenesis imply that receptor antagonists may selectively target the proliferative ECs 
forming neovessels without affecting the quiescent ECs of stabilized vessels. These spatio-
temporal properties of apelin signalling should strongly decrease the secondary effects 
induced by pharmacological agents targetting this pathway. 
At the present time, the pharmacology of this emergent pathway is still in its infancy. The 
first molecule reported to act on apelin receptors was ALX40-4C, but this peptide had a very 
low affinity for apelin receptors and a much better affinity for CXCR4 receptors (Zhou et al., 
2003). A first receptor antagonist resulting from substitution of apelin C-terminal amino acid 
was reported to block the hypotensive effects of apelin (Lee et al., 2005). However, in several 
other assays, this compound behaved as an agonist (Medhurst et al., 2003; Fan et al., 2003). 
Very recently, bicyclic peptides have been shown to represent competitive antagonists of 
apelin receptor (Macaluso et al., 2011). All these compounds are promising antiangiogenic 
agents for the treatment of pathological neovascularisations. 
So far, only one agonist molecule has been identified and characterized (Iturrioz et al., 2010). 
This nonpeptidic compound behaves as an agonist in various assays, but it does not have a 
very high affinity. Nevertheless, it provides the structural basis for the design of better 
molecules, which will be used for extension of the vascular network and revascularization in 
ischemic diseases. 
8. Conclusion and perspectives 
The discovery of new receptors and their ligands open avenues for the design of novel 
pharmacological agents for treating human diseases. In addition, if the discovered signalling 
pathway is linked to severe diseases or lethal pathologies, the development of structurally 
related drugs such as nonpeptidic agonists or antagonists will lead to important clinical 
applications. 
Apelin signalling fulfils these criteria as this emerging pathway represents a promising 
therapeutic target and requires the design of new pharmacological molecules in order to 
treat the prime causes of human mortality, such as heart failure and cancer, or severe 
diseases, such as limb ischemia and AMD.  
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